imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
levetiracetam actavis group
actavis group ptc ehf - levetiracetamul - epilepsie - antiepileptice, - grupa de medicamente actavis levetiracetam este indicat ca monoterapie in tratamentul convulsii parţiale-debut cu sau fara generalizare secundara la pacientii de 16 ani cu nou diagnosticat epilepsie. levetiracetam actavis group este indicat ca terapie adjuvantă:în tratamentul crizelor convulsive parțiale cu sau fără generalizare secundară, la adulți, copii și sugari de la vârsta de 1 lună, cu epilepsie;în tratamentul de crizele mioclonice la adulți și adolescenți începând cu vârsta de 12 ani cu epilepsie mioclonică juvenilă;în tratamentul primar generalizate tonico-clonice generalizate la adulți și adolescenți începând cu vârsta de 12 ani cu epilepsie generalizată idiopatică.
escitalopram actavis 10 mg
actavis ltd. - malta - escitalopramum - compr. film. - 10mg - antidepresive inhibitori selectivi ai recaptarii serotoninei
escitalopram actavis 20 mg
actavis ltd. - malta - escitalopramum - compr. film. - 20mg - antidepresive inhibitori selectivi ai recaptarii serotoninei
lopirel comprimate filmate 75 mg
actavis group ptc ehf. - clopidogrelum - comprimate filmate - 75 mg
vasotenz comprimate filmate 100 mg
actavis group ptc ehf. - losartanum - comprimate filmate - 100 mg
vasotenz comprimate filmate 50 mg
actavis group ptc ehf. - losartanum - comprimate filmate - 50 mg
vasotenz h comprimate filmate 100 mg + 25 mg
actavis group ptc ehf. - losartanum + hydrochlorthiazidum - comprimate filmate - 100 mg + 25 mg
vasotenz h comprimate filmate 50 mg + 12.5 mg
actavis group ptc ehf. - losartanum + hydrochlorthiazidum - comprimate filmate - 50 mg + 12.5 mg
zolmiles comprimate orodispersabile 2,5 mg
actavis group ptc ehf. - zolmitriptanum - comprimate orodispersabile - 2,5 mg